ANEW Medical (WENA) said Thursday it has partnered with researchers at Japan's Okinawa Research Center for Longevity Science for the development of its Klotho gene therapy in reducing age-related diseases.
Okinawa is among a set of global "Blue Zones" with high numbers of people who live to high ages and remain in good health.
ANEW said preliminary data suggests that the alpha-Klotho version of the human Klotho gene and its secreted alpha-Klotho protein isoform may contribute to long lifespans and protection against diseases such as Alzheimer's Disease. The company is developing a portfolio of therapies targeting the gene.
Price: 3.4200, Change: -0.20, Percent Change: -5.52
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.